The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Anti–Interleukin-12 Antibody for Active Crohn's Disease
Open accessAbstract
BACKGROUND: Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses. METHODS: This double-blind trial evaluated the safety and efficacy of a human monoclonal antibody against interleukin-12 (anti-interleukin-12) in 79 patients with active Crohn's disease. Patients were randomly assigned to receive seven weekly subcutaneous injections of 1 mg or 3 mg of anti-interleukin-12 per kilogram of body weight or placebo, with either a four-week interval between the first and second injection (Cohort 1) or no interruption between the two injections (Cohort 2). Safety was the primary end point, and the rates of clinical response (defined by a reduction in the score for the Crohn's Disease Activity Index [CDAI] of at least 100 points) and remission (defined by a CDAI score of 150 or less) were secondary end points. RESULTS: Seven weeks of uninterrupted treatment with 3 mg of anti-interleukin-12 per kilogram resulted in higher response rates than did placebo administration (75 percent vs. 25 percent, P=0.03). At 18 weeks of follow-up, the difference in response rates was no longer significant (69 percent vs. 25 percent, P=0.08). Differences in remission rates between the group given 3 mg of anti-interleukin-12 per kilogram and the placebo group in Cohort 2 were not significant at either the end of treatment or the end of follow-up (38 percent and 0 percent, respectively, at both times; P=0.07). There were no significant differences in response rates among the groups in Cohort 1. The rates of adverse events among patients receiving anti-interleukin-12 were similar to those among patients given placebo, except for a higher rate of local reactions at injection sites in the former group. Decreases in the secretion of interleukin-12, interferon-gamma, and tumor necrosis factor alpha by mononuclear cells of the colonic lamina propria accompanied clinical improvement in patients receiving anti-interleukin-12. CONCLUSIONS: Treatment with a monoclonal antibody against interleukin-12 may induce clinical responses and remissions in patients with active Crohn's disease. This treatment is associated with decreases in Th1-mediated inflammatory cytokines at the site of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Antibodies to interleukin 12 abrogate established experimental colitis in mice.
Neurath, M. F., Fuss, I., Kelsall, B. L., Stüber, E., & Strober, W. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1281 · Cited by 1,335
Self-citationTHE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses
Gately, M. K., Renzetti, L. M., Magram, J., Stern, A. S., Adorini, L., Gubler, U., & Presky, D. H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.495 · Cited by 1,231
Fuss, I. J., Neurath, M., Boirivant, M., Klein, J. S., de la Motte, C., Strong, S. A., Fiocchi, C., & Strober, W. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.3.1261 · Cited by 1,227
Self-citationD'Haens, G. R., Geboes, K., Peeters, M., Baert, F., Penninckx, F., & Rutgeerts, P. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70476-7 · Cited by 868
Monteleone, G., Biancone, L., Marasco, R., Morrone, G., Marasco, O., Luzza, F., & Pallone, F. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70128-8 · Cited by 573
Parronchi, P., Romagnani, P., Annunziato, F., Sampognaro, S., Becchio, A., Giannarini, L., Maggi, E., Pupilli, C., Tonelli, F., & Romagnani, S. (1997) · Europe PMC (PubMed Central) · Cited by 482
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease
Plevy, S. E., Landers, C. J., Prehn, J., Carramanzana, N. M., Deem, R. L., Shealy, D., & Targan, S. R. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.12.6276 · Cited by 385
Proinflammatory and Immunoregulatory Functions of Interleukin-12
Trinchieri, G. (1998) · International Reviews of Immunology · doi:10.3109/08830189809043002 · Cited by 290
Regulation of Interleukin-12 by Complement Receptor 3 Signaling
Marth, T., & Kelsall, B. L. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.11.1987 · Cited by 279
Simpson, S. J., Shah, S., Comiskey, M., de Jong, Y. P., Wang, B., Mizoguchi, E., Bhan, A. K., & Terhorst, C. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1225 · Cited by 278
Novel IL-12 family members shed light on the orchestration of Th1 responses
Brombacher, F. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00067-x · Cited by 269
Anti–interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice
Fuss, I. J., Marth, T., Neurath, M. F., Pearlstein, G. R., Jain, A., & Strober, W. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70392-6 · Cited by 268
Self-citationDavidson, N. J., Hudak, S. A., Lesley, R., Menon, S., Leach, M. W., & Rennick, D. M. (1998) · PubMed · Cited by 250
XII. IL-10-deficient (IL-10−/−) mice and intestinal inflammation
Rennick, D. M., & Fort, M. M. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.6.g829 · Cited by 225
Su, C., Lichtenstein, G. R., Krok, K., Brensinger, C. M., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.024 · Cited by 212
Davidson, N. J., Hudak, S. A., Lesley, R. E., Menon, S., Leach, M. W., & Rennick, D. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3143 · Cited by 208
Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome
Jain, A., Atkinson, T. P., Lipsky, P. E., Slater, J. E., Nelson, D. L., & Strober, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5891 · Cited by 116
Self-citationIL-23: A Cytokine That Acts on Memory T Cells
Frucht, D. M. (2002) · Science Signaling · doi:10.1126/stke.2002.114.pe1 · Cited by 63
Fais, S., Capobianchi, M. R., Silvestri, M., et al. (1994) · Journal of Interferon Research · doi:10.1089/jir.1994.14.235 · Cited by 61
Monteleone, G., Parrello, T., Monteleone, I., Tammaro, S., Luzza, F., & Pallone, F. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.00991.x · Cited by 31
Cited by
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Self-citationAbraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Self-citationIL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842
Metadata
- Authors
- Mannon, P. J., Fuss, I. J., Mayer, L., Elson, C. O., Sandborn, W. J., Present, D., Dolin, B., Goodman, N., Groden, C., Hornung, R. L., Quezado, M., Neurath, M. F., Salfeld, J., Veldman, G. M., Schwertschlag, U., & Strober, W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2069-2079
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2131727319
- Cited by
- 848
- References
- 22
- FWCI
- 38.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.